

## PHILIPS DECLARES COMPATIBILITY WITH IMRICOR

### HIGHLIGHTS

- Philips has issued a Third Party Product Compatibility Declaration covering Imricor's capital equipment and consumables – for use with Philips MR systems
- Declaration covers five initial MR systems and four MR system upgrades running software versions R12.1.1 or greater
- Imricor and Philips to co-sponsor iMR sessions at ESC Congress in August, the world's leading cardiology meeting

**7 August 2026** – Melbourne, Australia (**6 August 2026** – Minneapolis, MN, United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that Philips Medical Systems Nederland B.V. (Philips), one of the world's largest medical imaging companies, has issued a Third Party Product Compatibility Declaration, covering Imricor's interventional magnetic resonance (iMR) products when used with Philips magnetic resonance (MR) systems.

The declaration covers Imricor products working alongside five initial MR systems and four MR system upgrades, all running software versions R12.1.1 or greater. Imricor products tested alongside Philips MR systems include NorthStar®, the Advantage-MR® system, Vision-MR® Ablation Catheters 2.0 (both 32mm and 42mm versions), Vision-MR Ablation Cable Set 2.0, Vision MR Diagnostic Catheter, Vision-MR Diagnostic Cable 2.0, and Vision-MR Dispersive Electrode.

### Unlocking iMR labs with Philips MR systems

The Philips Third Party Product Compatibility Declaration is the last step within Philips to allow Imricor's NorthStar mapping and guidance system to connect and operate in a commercial clinical setting with Philips MR scanners. Imricor and Philips may now collaborate to enable NorthStar-guided procedures in iMR facilities with Philips MR systems.

**Imricor's Chair and CEO, Steve Wedan, commented:** "Today's compatibility statement from Philips means we can move to install the latest Imricor technology, including NorthStar, at Philips iMR sites, such as the very important German Heart Center of Charité in Berlin, under the direction of Professors Dr Gerhard Hindricks and Dr Sebastian Kelle. We are thrilled to complete this final step with Philips and progress iMR procedures at Philips-based iMR sites."



## Partnering at ESC Congress 2026

Imricor and Philips are partnering at the European Society of Cardiology (ESC) Congress in Munich to co-sponsor the *ESC Interventional MR Tutorials* on Saturday, August 29<sup>th</sup> at 11am and Sunday, August 30<sup>th</sup> at 2pm.

Both sessions will be led by Professor Steven Chamuleau, head of cardiology at the Amsterdam University Medical Center, and consist of 30-minute presentations followed by 15 minutes of Q&A. Topics include:

- What it takes to set up an iMR lab, from structural layouts to workflows
- Real-world experiences with MR-guided EP and ablation with Imricor, including case examples, clinical experiences, and benefits for atrial and ventricular treatments
- Other iMR cardiovascular interventions, such as cardiac catheterisation

**Imricor's VP of Marketing and Business Development, Nick Twohy, noted:** "We are working closely with Philips on the ESC programs as well as other exciting near-term projects, and I think this level of commitment to interventional MR from a medtech giant such as Philips speaks volumes about the maturity and readiness of iMR products and technology, as well as the size of the opportunity we all see in front of us."

## ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

### Media and Investor Relations Contacts:

Simon Hinsley  
Executive Director, NWR  
simon@nwrcommunications.com.au  
+61 401 909 653

Nick Corkill  
VP Corporate Strategy, Imricor  
nick.corkill@imricor.com  
+61 450 475 633

### About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

### Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for interventional MR (iMR) procedures. The Company's products include capital equipment, such as the NorthStar<sup>®</sup> Mapping System and the Advantage-MR<sup>®</sup> EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used in an iMR lab.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar is cleared in the US.



### Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.